Aimee Merino is an Oncology physician affiliated with University of Minnesota Medical Center. OpenAlex indexes 35 publications with 654 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
909 Fulton St SE
Minneapolis, MN 554554800
Telephone
612-672-7422Provider last certified this registry record 11 Jan 2024.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202530 payments$60,146openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202575 payments$55,681openpaymentsdata.cms.gov ↗
- Legend Biotech USA Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.5%Thalidomide Analog33.4%Revlimid55%Lenalidomide27%Pomalyst18%Part D<11 patientsProteasome Inhibitor4.1%Ninlaro100%Part D<11 patientsDermatology
27.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.3%Acyclovir100%Part D≥42 patientsSensory organs
11.4%Corticosteroid11.4%Dexamethasone100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma
University of Minnesota
FY2025$149,059K08CA255426 - Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma
University of Minnesota
FY2024$149,059K08CA255426 - Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma
University of Minnesota
FY2023$148,665K08CA255426
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- B7-H3 expression impacts outcomes in myeloma and is targetable with an NK cell engager
Blood Immunology & Cellular Therapy
2026 - B7-H3 is Associated with Worse Outcomes in Newly Diagnosed Myeloma and Can Be Targeted with a Tri-Specific Killer Engager
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Troy Lund, MD
University of Minnesota Medical Center
Susan Kline, MD
University of Minnesota Medical Center
Thaddeus Walczak, MD
University of Minnesota Medical Center
Jay Krachmer, MD
University of Minnesota Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”